Published February 6, 2026 in Future readiness • 10 min read • 
Audio available
The gap between future-ready and future-fragile companies shows up in the numbers. Against a backdrop of geopolitical tension and mass AI deployment, some firms are turning disruption into an advantage, while others are discovering that yesterday’s strengths trap them in yesterday’s game.
The 2025 Future Readiness Indicator ranks 49 technology companies, 27 pharmaceutical companies, and 41 fashion companies on their future readiness. Those dominating the top of this year’s indicator combine supply chain agility with an ability to adapt quickly to shifting regulations. The winners move capital, talent, and capabilities across borders and product lines faster than the world can throw up new constraints.
These companies often have the capability to orchestrate an entire ecosystem rather than relying on a single product or service. They are laser-focused on performing in the near term, while also transforming the enterprise.
Leading the way means executing the best – not spending the most. In a world where AI is breaking barriers, the future belongs to companies that give the seamless experience that customers have come to expect.Â
Future-ready companies design supply chains that can be rerouted and operating models that can live with fast-moving regulation.
In the technology sector, Nvidia, Microsoft, Alphabet, and Meta proved that mastery of the entire AI stack (i.e., infrastructure, software, and data) and building the capabilities that flow from it keep you ahead amid rapid technological advancement and trade tensions. They stand in sharp contrast to firms that did not diversify or stayed tied to legacy hardware systems and find themselves without the capacity to adapt.
In pharmaceuticals, the top-ranked companies – Johnson & Johnson, Roche, and AstraZeneca – have mastered the whole pharmaceutical value chain and are building next-generation therapeutic platforms. By contrast, companies centered on older product portfolios are navigating upcoming patent expirations and rising cost constraints, making platform innovation more important than ever.
In fashion, the top of the indicator is dominated by models of platform-based resilience. The diversified luxury “super-conglomerate” LVMH reclaims the top spot, demonstrating that a portfolio of iconic brands provides an unparalleled moat against volatility. It is joined by the vertically integrated, data-driven ecosystem models of Inditex (Zara), which rises to second place, and Hermès. These companies are insulated from market shocks by their non-negotiable brand equity, mastery of their supply chains, and vast cash reserves.
Our research shows that the companies leading in the technology, pharmaceutical, and fashion sectors have succeeded in four key areas:
In technology, for decades, software was the barrier to entry; now it’s silicon and the supply chains that produce it. The most future-ready companies have mastered the full AI stack and control every layer of the AI ecosystem: chips, cloud infrastructure, and the user interface. This ability to rebuild from the inside out translates into the ability to shift capabilities at the necessary speed to stay ahead. US tech giants have committed to investing billions in infrastructure, including data centers, across the US. This signals a shift from offshoring manufacturing to onshoring the infrastructure that powers AI, cloud computing, and the digital economy.
In China, companies are racing to build self-sufficient AI ecosystems but have struggled due to limited access to AI hardware amid growing geopolitical tensions. This pressure is forcing a rapid push toward domestic stacks, from chips to data centers, often powered by relatively cheap energy and large-scale, state-backed infrastructure. Smart tech companies, even when competing outside China, keep a close eye on what is happening on the mainland. Companies that have figured out how to play both sides (like Samsung) are thriving.
In pharmaceuticals, companies moving beyond a pill-only model and embracing next-generation integrated health platforms are best placed to navigate policy upheavals such as the Inflation Reduction Act of 2022 (IRA). With apps, in-home monitoring, and connected services, they can justify the value of treatments as embedded outcomes rather than just drugs. Supply-chain security is as critical as scientific innovation: a sizable portion of the world’s active pharmaceutical ingredients (APIs) originate in China. If China were to impose export controls, Western manufacturers would not be able to ramp up production overnight.
Data from the fashion industry shows that supply-chain transformation is accelerating. Fast-fashion leaders thrive on fast-cycle innovation and global agility, using store networks as a sensing network to translate runway looks into shelf-ready products in a matter of weeks. Trend forecasting has become just as critical. Some brands deploy AI to analyze social media streams to spot emerging styles before consumers even articulate them. The result? Fewer misses, less overproduction, and far less stale inventory clogging the system.
Established players built around a traditional pill-focused model are finding it harder to keep pace amid faster innovation cycles and upcoming patent cliffs.
In technology, companies tethered to legacy hardware are finding it harder to adapt to the AI-centric world. Those that have failed to diversify struggle to escape commodity traps (hardware-heavy and consumer electronics firms are particularly guilty of this). Those tech companies with a diversified offering can shift focus as AI and other technologies change the way users interact with platforms.
Established players built around a traditional pill-focused model are finding it harder to keep pace amid faster innovation cycles and upcoming patent cliffs.
In pharma, established players built around a traditional pill-focused model are finding it harder to keep pace amid faster innovation cycles and upcoming patent cliffs. Future-ready companies leverage diversification to cross-pollinate innovation and buffer risk. Companies built around one or two major franchises face more volatility in the ranking simply because concentration increases exposure to regulatory shifts and competitive pressure. Drugmakers with blockbuster products are entering an era where pricing is more tightly regulated or negotiated in the US. To compete, leading companies are striking R&D partnerships or acquiring biotech companies to reset their trajectory. Â
In fashion, the leaders show that diversification provides resilience in tough times. Companies with diverse customer bases and portfolios are more insulated against a single market downturn. Narrowly focused brands cap their own potential: one bad season can knock out all of their momentum.
In pharma, the leading companies have discovered that AI will augment their ability to overcome challenges facing the sector, including the speed and cost of drug trials.
In technology, the leading companies are not necessarily those that spend the most, but those that execute the best. Future-ready companies have made strides in the old-fashioned way: fixing problems and meeting deadlines. They have implemented AI initiatives that deliver measurable business value, while others have let innovation run riot with no clear revenue streams. In the AI era, innovation must pay for itself. Leaders not only demonstrate why controlling the production of AI matters, but they also use AI to transform the way they work to generate revenue growth.
In pharma, the leading companies have discovered that AI will augment their ability to overcome challenges facing the sector, including the speed and cost of drug trials. Companies harnessing AI to speed up the process through tech partnerships can get one step ahead.
In fashion, future-ready companies turn ideas into tangible results. They use data and digital tools to improve hit rates, tighten inventories, and raise full-price sell-through. The best performers are not experimenting for the sake of it; they are using technology to reduce waste, lower returns, and move products through the system faster. Their execution shows up in revenue growth and stronger margins. Others treat innovation as a slogan rather than a working practice.
In technology, future-ready companies are eliminating entire steps in the user journey, not just eliminating friction. The winners own the interface, the data, and the workflow. They turn what used to be a series of separate apps into one continuous experience.
China’s WeChat demonstrated this early. A simple chat window became the entry point for paying bills, booking medical visits, buying groceries, and managing daily life. In India, WhatsApp offers an end-to-end grocery shopping experience that lets users browse, order, and pay without leaving the conversation. Once people stay inside your interface, you control the whole journey.
Whether consumer- or enterprise-facing, the pattern is consistent. As hardware, software, and AI come together, the advantage goes to companies that orchestrate the entire ecosystem and sit at the most frequent points of user interaction, embedding themselves into daily activity as the interface people rely on.
In pharmaceuticals, the same blurring of boundaries is taking place. The most future-ready companies no longer define themselves as pill manufacturers. They pair therapies with devices, apps, and data services to improve outcomes and strengthen patient engagement. One such example is an asthma treatment with a smart inhaler sensor and a companion app, enabling patients and clinicians to monitor usage and symptoms in real time. The treatment is no longer just a drug; it’s an integrated service. These leaders also lower the barriers for startups and tech partners to join their ecosystem. As healthcare shifts toward a patient-centered ecosystem, companies that cling to a narrow pill-only strategy and remain internally siloed risk losing relevance.
In fashion, the leaders make the entire customer journey feel effortless, whether online or in-store. In fast fashion, apps and stores operate as a single system. Customers can check real-time inventory, reserve fitting rooms, pick up online orders within hours, and use a mobile checkout that reduces waiting to almost zero. RFID-enabled logistics  update online availability the moment an item is scanned in a store. Luxury leaders have taken a different, yet equally customer-centric approach. Clients move smoothly from online browsing to in-store appointments to private clientele services that track preferences, purchase history, and upcoming product releases.
The pattern is clear. The leaders remove friction and let customers move naturally between channels. This builds loyalty while keeping the technology in the background.
Are you building a company that can keep winning as the game keeps changing? The leaders in tech, pharma, and fashion point to a repeatable playbook.
The ability to navigate geopolitical tension has become a core competency. Future-ready companies design supply chains that can be rerouted and operating models that can live with fast-moving regulation. They don’t just optimize one factory or one country; they learn to move across systems of suppliers, partners, and platforms so that a shock in one part doesn’t bring the whole machine to a halt.
The strongest companies don’t wait for a crisis before they diversify. They build second and third engines of growth while the core business is still healthy. That means new categories, R&D partnerships, and targeted acquisitions, so that when technology shifts or regulation bites, they can pivot rather than start from scratch.
You don’t have to be the biggest player. What matters is repeatedly staying slightly ahead of the next turn. The leaders in our 2025 report are ruthless about execution. They deploy AI where it changes outcomes, prune projects that do not, and keep redirecting capital to what works. Innovation that cannot pay its own way is a distraction.
In markets crowded with choice, strategy lies in the experience. The most future-ready companies make things effortless for customers and users, whether that means a single interface for an entire digital journey or a health pathway that runs smoothly from diagnosis to continuous monitoring at home. Personalization is also the baseline. Future-ready leaders orchestrate the journey so technology fades into the background.
Jialu Shan, Lawrence Tempel, and Alexandre Sonderegger contributed to this article.
A century of progress in medical science and healthier living has gifted us extra decades of productive life. Avivah Wittenberg-Cox suggests ways to ensure that you and your organization are ready to...
Audio available
The biggest risk isn’t that AI under‑delivers. It’s that organizations overreact or underreact. Here we unpack the four zones of AI readiness and explain why building sandboxes is the best way forward....
Audio available
The Swiss-based energy group is plotting a course toward a renewables-focused future, without abandoning its traditional customer base. Here we explore five key principles that have underpinned the company’s success....
Audio available
One year after launch, AI risk tracker underlines worrying implications of accelerating AI adoption....
Explore first person business intelligence from top minds curated for a global executive audience